Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones

Thromb Haemost. 2004 Apr;91(4):674-82. doi: 10.1160/TH03-06-0384.


Adipose tissue produces substantial amounts of plasminogen activator inhibitor type-1 (PAI-1), an established cardiovascular risk factor. This study evaluated PAI-1 expression in human adipose tissue in response to thiazolidinediones, insulin sensitising drugs activating peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Troglitazone, rosiglitazone, and ciglitazone significantly reduced PAI-1 protein expression in human preadipocytes under basal conditions and after stimulation of the cells with TGF-beta. Pioglitazone had no effect. In human adipocytes all four thiazolidinediones significantly attenuated PAI-1 expression. Signalling appeared to be mediated via PPAR-gamma and effects reflected, at least in part, changes in transcription. Accordingly, patients with insulin resistance may benefit from treatment with thiazolidinediones with respect to diminution of PAI-1 expression in adipose tissue and consequent potential reduction of cardiovascular risk.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipocytes / cytology
  • Adipocytes / drug effects
  • Adipose Tissue / cytology
  • Adipose Tissue / drug effects*
  • Adipose Tissue / metabolism
  • Cells, Cultured
  • Chromans / pharmacology
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Insulin Resistance
  • PPAR gamma / metabolism
  • Pioglitazone
  • Plasminogen Activator Inhibitor 1 / analysis
  • Plasminogen Activator Inhibitor 1 / biosynthesis*
  • Rosiglitazone
  • Thiazolidinediones / pharmacology*
  • Transcription, Genetic
  • Troglitazone


  • Chromans
  • Hypoglycemic Agents
  • PPAR gamma
  • Plasminogen Activator Inhibitor 1
  • Thiazolidinediones
  • Rosiglitazone
  • Troglitazone
  • ciglitazone
  • Pioglitazone